Pharmacology - Research Publications

Permanent URI for this collectionhttps://kr.cup.edu.in/handle/32116/111

Browse

Author: search.filters.author.Bali, AnjanaSubject: search.filters.subject.Neuropathic pain

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Demystifying the dual role of the angiotensin system in neuropathic pain
    (Churchill Livingstone, 2022-05-26T00:00:00) Kaur, Sahibpreet; Bali, Anjana; Singh, Nirmal; Jaggi, Amteshwar Singh
    Neuropathic Pain is caused by damage to a nerve or disease of the somatosensory nervous system. Apart from the blood pressure regulating actions of angiotensin ligands, studies have shown that it also modulates neuropathic pain. In the animal models including surgical, chemotherapeutic, and retroviral-induced neuropathic pain, an increase in the levels of angiotensin II has been identified and it has been proposed that an increase in angiotensin II may participate in the induction of neuropathic pain. The pain-inducing actions of the angiotensin system are primarily due to the activation of AT1 and AT2 receptors, which trigger the diverse molecular mechanisms including the induction of neuroinflammation to initiate and maintain the state of neuropathic pain. On the other hand, the pain attenuating action of the angiotensin system has been attributed to decreasing in the levels of Ang(1�7), and Ang IV and an increase in the levels of bradykinin. Ang(1�7) may attenuate neuropathic pain via activation of the spinal Mas receptor. However, the detailed molecular mechanism involved in Ang(1�7) and Ang IV-mediated pain attenuating actions needs to be explored. The present review discusses the dual role of angiotensin ligands in neuropathic pain along with the possible mechanisms involved in inducing or attenuating the state of neuropathic pain. � 2022 Elsevier Ltd
  • No Thumbnail Available
    Item
    Exploring the role of cAMP in gabapentin-mediated pain attenuating effects in chroniconstriction injury model in rats
    (Faculdade de Ciencias Farmaceuticas (Biblioteca), 2022-06-07T00:00:00) Sharma, Deepankshi; Jaggi, Amteshwar Singh; Arora, Kiran; Bali, Anjana
    It has been shown that an increase in cAMP leads to pain sensitization and gabapentin is shown to decrease cAMP levels. However, the impact of drugs modulating cAMP levels on analgesic actions of gabapentin is not studied. The present study investigates the effect of milrinone on pain attenuating effects of gabapentin in chronic constriction injury (CCI). Neuropathic pain was induced by putting four loose ligatures around the sciatic nerve. The pain assessment was done by noting the paw withdrawal threshold in the pinprick test, paw withdrawal latency in hot plate test and paw withdrawal duration in acetone drop test before surgery and on 14th-day post-surgery. There was a significant development of cold allodynia, mechanical and heat hyperalgesia on 14th day in CCI rats. Gabapentin (100 mg/kg) treatment for 14 days significantly attenuated pain, while milrinone (50 mg/kg) treatment for 14 days significantly exacerbated neuropathic pain in CCI-subjected rats. Milrinone (30 and 50 mg/kg) also attenuated analgesic actions of gabapentin in CCI-subjected rats, suggests that gabapentin may abolish neuropathic pain by increasing the intracellular levels of cAMP in CCI-subjected rats. � 2022, Faculdade de Ciencias Farmaceuticas (Biblioteca). All rights reserved.